The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
PEGylated Protein Therapeutics-Global Market Insights and Sales Trends 2024
Synopsis
PEGylating has been widely used as a post-production modification methodology for improving biomedical efficacy and physicochemical properties of therapeutic proteins since the first PEGylated product was approved by Food and Drug Administration in the early 1990s.
The global PEGylated Protein Therapeutics market size is expected to reach US$ 4920.2 million by 2029, growing at a CAGR of 3.8% from 2023 to 2029. The market is mainly driven by the significant applications of PEGylated Protein Therapeutics in various end use industries. The expanding demands from the Cancer, Autoimmune Disease, Hepatitis and Multiple Sclerosis, are propelling PEGylated Protein Therapeutics market. Colony Stimulating Factor, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Interferon segment is estimated at % CAGR for the next seven-year period.
The major players in global PEGylated Proteins market include UCB, Pfizer, etc. The top 2 players occupy about 60% shares of the global market. North America and Europe are main markets, they occupy over 60% of the global market. Colony Stimulating Factors and Interferons are two main types, with a share over 40% altogether. Rheumatoid Arthritis & Crohn's Disease and Cancer Treatment are two key applications, they hold about 60% shares.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for PEGylated Protein Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global PEGylated Protein Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global PEGylated Protein Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, PEGylated Protein Therapeutics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of PEGylated Protein Therapeutics covered in this report include Merck, Pfizer, UCB, Amgen, AstraZeneca, Biogen, Roche, Horizon Pharma and Leadiant Biosciences, etc.
The global PEGylated Protein Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Merck
Pfizer
UCB
Amgen
AstraZeneca
Biogen
Roche
Horizon Pharma
Leadiant Biosciences
Global PEGylated Protein Therapeutics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global PEGylated Protein Therapeutics market, Segment by Type:
Colony Stimulating Factor
Interferon
Erythropoietin (EPO)
Recombinant Factor VIII
Monoclonal Antibody
Enzyme
Others
Global PEGylated Protein Therapeutics market, by Application
Cancer
Autoimmune Disease
Hepatitis
Multiple Sclerosis
Hemophilia
Gastrointestinal Disorder
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of PEGylated Protein Therapeutics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
PEGylating has been widely used as a post-production modification methodology for improving biomedical efficacy and physicochemical properties of therapeutic proteins since the first PEGylated product was approved by Food and Drug Administration in the early 1990s.
The global PEGylated Protein Therapeutics market size is expected to reach US$ 4920.2 million by 2029, growing at a CAGR of 3.8% from 2023 to 2029. The market is mainly driven by the significant applications of PEGylated Protein Therapeutics in various end use industries. The expanding demands from the Cancer, Autoimmune Disease, Hepatitis and Multiple Sclerosis, are propelling PEGylated Protein Therapeutics market. Colony Stimulating Factor, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Interferon segment is estimated at % CAGR for the next seven-year period.
The major players in global PEGylated Proteins market include UCB, Pfizer, etc. The top 2 players occupy about 60% shares of the global market. North America and Europe are main markets, they occupy over 60% of the global market. Colony Stimulating Factors and Interferons are two main types, with a share over 40% altogether. Rheumatoid Arthritis & Crohn's Disease and Cancer Treatment are two key applications, they hold about 60% shares.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for PEGylated Protein Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global PEGylated Protein Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global PEGylated Protein Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, PEGylated Protein Therapeutics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of PEGylated Protein Therapeutics covered in this report include Merck, Pfizer, UCB, Amgen, AstraZeneca, Biogen, Roche, Horizon Pharma and Leadiant Biosciences, etc.
The global PEGylated Protein Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Merck
Pfizer
UCB
Amgen
AstraZeneca
Biogen
Roche
Horizon Pharma
Leadiant Biosciences
Global PEGylated Protein Therapeutics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global PEGylated Protein Therapeutics market, Segment by Type:
Colony Stimulating Factor
Interferon
Erythropoietin (EPO)
Recombinant Factor VIII
Monoclonal Antibody
Enzyme
Others
Global PEGylated Protein Therapeutics market, by Application
Cancer
Autoimmune Disease
Hepatitis
Multiple Sclerosis
Hemophilia
Gastrointestinal Disorder
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of PEGylated Protein Therapeutics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of PEGylated Protein Therapeutics
1.1 PEGylated Protein Therapeutics Market Overview
1.1.1 PEGylated Protein Therapeutics Product Scope
1.1.2 PEGylated Protein Therapeutics Market Status and Outlook
1.2 Global PEGylated Protein Therapeutics Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global PEGylated Protein Therapeutics Market Size by Region (2018-2029)
1.4 Global PEGylated Protein Therapeutics Historic Market Size by Region (2018-2023)
1.5 Global PEGylated Protein Therapeutics Market Size Forecast by Region (2024-2029)
1.6 Key Regions, PEGylated Protein Therapeutics Market Size (2018-2029)
1.6.1 North America PEGylated Protein Therapeutics Market Size (2018-2029)
1.6.2 Europe PEGylated Protein Therapeutics Market Size (2018-2029)
1.6.3 Asia-Pacific PEGylated Protein Therapeutics Market Size (2018-2029)
1.6.4 Latin America PEGylated Protein Therapeutics Market Size (2018-2029)
1.6.5 Middle East & Africa PEGylated Protein Therapeutics Market Size (2018-2029)
2 PEGylated Protein Therapeutics Market by Type
2.1 Introduction
2.1.1 Colony Stimulating Factor
2.1.2 Interferon
2.1.3 Erythropoietin (EPO)
2.1.4 Recombinant Factor VIII
2.1.5 Monoclonal Antibody
2.1.6 Enzyme
2.1.7 Others
2.2 Global PEGylated Protein Therapeutics Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global PEGylated Protein Therapeutics Historic Market Size by Type (2018-2023)
2.2.2 Global PEGylated Protein Therapeutics Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America PEGylated Protein Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.2 Europe PEGylated Protein Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific PEGylated Protein Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America PEGylated Protein Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa PEGylated Protein Therapeutics Revenue Breakdown by Type (2018-2029)
3 PEGylated Protein Therapeutics Market Overview by Application
3.1 Introduction
3.1.1 Cancer
3.1.2 Autoimmune Disease
3.1.3 Hepatitis
3.1.4 Multiple Sclerosis
3.1.5 Hemophilia
3.1.6 Gastrointestinal Disorder
3.1.7 Others
3.2 Global PEGylated Protein Therapeutics Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global PEGylated Protein Therapeutics Historic Market Size by Application (2018-2023)
3.2.2 Global PEGylated Protein Therapeutics Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America PEGylated Protein Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.2 Europe PEGylated Protein Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific PEGylated Protein Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America PEGylated Protein Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa PEGylated Protein Therapeutics Revenue Breakdown by Application (2018-2029)
4 PEGylated Protein Therapeutics Competition Analysis by Players
4.1 Global PEGylated Protein Therapeutics Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in PEGylated Protein Therapeutics as of 2022)
4.3 Date of Key Players Enter into PEGylated Protein Therapeutics Market
4.4 Global Top Players PEGylated Protein Therapeutics Headquarters and Area Served
4.5 Key Players PEGylated Protein Therapeutics Product Solution and Service
4.6 Competitive Status
4.6.1 PEGylated Protein Therapeutics Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Merck
5.1.1 Merck Profile
5.1.2 Merck Main Business
5.1.3 Merck PEGylated Protein Therapeutics Products, Services and Solutions
5.1.4 Merck PEGylated Protein Therapeutics Revenue (US$ Million) & (2018-2023)
5.1.5 Merck Recent Developments
5.2 Pfizer
5.2.1 Pfizer Profile
5.2.2 Pfizer Main Business
5.2.3 Pfizer PEGylated Protein Therapeutics Products, Services and Solutions
5.2.4 Pfizer PEGylated Protein Therapeutics Revenue (US$ Million) & (2018-2023)
5.2.5 Pfizer Recent Developments
5.3 UCB
5.3.1 UCB Profile
5.3.2 UCB Main Business
5.3.3 UCB PEGylated Protein Therapeutics Products, Services and Solutions
5.3.4 UCB PEGylated Protein Therapeutics Revenue (US$ Million) & (2018-2023)
5.3.5 Amgen Recent Developments
5.4 Amgen
5.4.1 Amgen Profile
5.4.2 Amgen Main Business
5.4.3 Amgen PEGylated Protein Therapeutics Products, Services and Solutions
5.4.4 Amgen PEGylated Protein Therapeutics Revenue (US$ Million) & (2018-2023)
5.4.5 Amgen Recent Developments
5.5 AstraZeneca
5.5.1 AstraZeneca Profile
5.5.2 AstraZeneca Main Business
5.5.3 AstraZeneca PEGylated Protein Therapeutics Products, Services and Solutions
5.5.4 AstraZeneca PEGylated Protein Therapeutics Revenue (US$ Million) & (2018-2023)
5.5.5 AstraZeneca Recent Developments
5.6 Biogen
5.6.1 Biogen Profile
5.6.2 Biogen Main Business
5.6.3 Biogen PEGylated Protein Therapeutics Products, Services and Solutions
5.6.4 Biogen PEGylated Protein Therapeutics Revenue (US$ Million) & (2018-2023)
5.6.5 Biogen Recent Developments
5.7 Roche
5.7.1 Roche Profile
5.7.2 Roche Main Business
5.7.3 Roche PEGylated Protein Therapeutics Products, Services and Solutions
5.7.4 Roche PEGylated Protein Therapeutics Revenue (US$ Million) & (2018-2023)
5.7.5 Roche Recent Developments
5.8 Horizon Pharma
5.8.1 Horizon Pharma Profile
5.8.2 Horizon Pharma Main Business
5.8.3 Horizon Pharma PEGylated Protein Therapeutics Products, Services and Solutions
5.8.4 Horizon Pharma PEGylated Protein Therapeutics Revenue (US$ Million) & (2018-2023)
5.8.5 Horizon Pharma Recent Developments
5.9 Leadiant Biosciences
5.9.1 Leadiant Biosciences Profile
5.9.2 Leadiant Biosciences Main Business
5.9.3 Leadiant Biosciences PEGylated Protein Therapeutics Products, Services and Solutions
5.9.4 Leadiant Biosciences PEGylated Protein Therapeutics Revenue (US$ Million) & (2018-2023)
5.9.5 Leadiant Biosciences Recent Developments
6 North America
6.1 North America PEGylated Protein Therapeutics Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe PEGylated Protein Therapeutics Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific PEGylated Protein Therapeutics Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America PEGylated Protein Therapeutics Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa PEGylated Protein Therapeutics Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 PEGylated Protein Therapeutics Market Dynamics
11.1 PEGylated Protein Therapeutics Industry Trends
11.2 PEGylated Protein Therapeutics Market Drivers
11.3 PEGylated Protein Therapeutics Market Challenges
11.4 PEGylated Protein Therapeutics Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
